Organization
Affiliated Drum Tower hospital
1 abstract
Abstract
Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Peking University First Hospital, Affiliated Drum Tower hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,